Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Telix Pharmaceuticals (TLX) Goodwill & Intangibles (2023 - 2025)

Telix Pharmaceuticals has reported Goodwill & Intangibles over the past 3 years, most recently at $791.8 million for Q4 2025.

  • Quarterly Goodwill & Intangibles rose 133.77% to $791.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $791.8 million through Dec 2025, up 133.77% year-over-year, with the annual reading at $791.8 million for FY2025, 190.96% up from the prior year.
  • Goodwill & Intangibles was $791.8 million for Q4 2025 at Telix Pharmaceuticals, up from $338.7 million in the prior quarter.
  • Over five years, Goodwill & Intangibles peaked at $791.8 million in Q4 2025 and troughed at $71.4 million in Q4 2023.
  • The 3-year median for Goodwill & Intangibles is $338.7 million (2024), against an average of $400.6 million.
  • Year-over-year, Goodwill & Intangibles soared 374.47% in 2024 and then surged 133.77% in 2025.
  • A 3-year view of Goodwill & Intangibles shows it stood at $71.4 million in 2023, then soared by 374.47% to $338.7 million in 2024, then surged by 133.77% to $791.8 million in 2025.
  • Per Business Quant, the three most recent readings for TLX's Goodwill & Intangibles are $791.8 million (Q4 2025), $338.7 million (Q4 2024), and $71.4 million (Q4 2023).